Beraprost sodium

PreclinicalSmall molecule

LLung Biotechnology PBC

Beraprost sodium is one of 44 small molecule programs targeting Diabetic Nephropathy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetic NephropathyActive, not recruiting

HemodialysisUnknown status

Diabetic NephropathyPreclinical

Active, not recruiting

HemodialysisPreclinical

Unknown status

Competition

Competitive Landscape

49 competitors in Diabetic Nephropathy

#DrugCompanyPhaseTrials

Aldactone

Pfizer

Approved

6 2

Farxiga

AstraZeneca

Approved

3 3

Zemplar

AbbVie

Approved

1 4

Lorelco

Sanofi

Approved

1 5

Byetta

AstraZeneca

Approved

1 6

Rocaltrol

Jazz Pharmaceuticals

Approved

1 7

Avapro

Sanofi

Approved

1 8

Corlanor

Defitelio

Kerendia

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pulmonary Arterial Hypertension3 trials

An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients

Completed·LLung Biotechnology PBC·Phase 2·NCT00792571·18 enrolled

Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients

Completed·LLung Biotechnology PBC·Phase 2·NCT00990314·31 enrolled

Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)

Completed·LLung Biotechnology PBC·Phase 2·NCT00989963·36 enrolled

Microcirculation1 trial

Evaluation of Nail Fold Microcirculation in CKD

Unknown status·TThe Affiliated Hospital of Xuzhou Medical University·Phase 4·NCT03682952·100 enrolled

PAH1 trial

A Multi-Center, Open-Label, Multiple Dose, Dose Finding Study Exploring the Safety and Tolerability of Beraprost Sodium Modified Release in PAH Patients

Completed·LLung Biotechnology PBC·Phase 2·NCT00781885·19 enrolled

Hemodialysis1 trial

Effect of Beraprost Sodium (Berasil) on Hemodialysis

Unknown status·YYonsei University·N/A·NCT03142360·60 enrolled

Renal Impairment1 trial

A Pharmacokinetic Study of TRK-100STP in Japanese Patients With Renal Impairment

Completed·TToray Industries, Inc·Phase 1·NCT01443429·24 enrolled

3 more indications

Acute1 trial

Protective Effect of Beraprost Sodium Tablets on Reperfusion Therapy for Acute STEMI

Unknown status·SShenzhen People's Hospital·Phase 1·NCT05103813·100 enrolled

Diabetic Nephropathy1 trial

Beraprost Sodium and Arterial Stiffness in Patients With Type 2 Diabetic Nephropathy

Unknown status·SSeoul National University Hospital·N/A·NCT01796418·102 enrolled

Children1 trial

Efficacy of Beraprost in Lowering Pulmonary Arterial Pressure in Children

Completed·—·Phase 4·NCT03431649·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Beraprost sodium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Beraprost sodium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Beraprost sodium. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Lung Biotechnology PBC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: LLung Biotechnology PBC

Beraprost sodium

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pulmonary Arterial Hypertension3 trials

Microcirculation1 trial

PAH1 trial

Hemodialysis1 trial

Renal Impairment1 trial

Acute1 trial

Diabetic Nephropathy1 trial

Children1 trial

References

Drug Info

Quick Facts

Related News